Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
SpringWorks Therapeutics, Inc.: Certificate of incorporation amended and restated in its entirety at the effective time of the merger.
- Change
- charter amendment
Exact text from the filing
at the Effective Time, SpringWorks’ certificate of incorporation and bylaws were each amended and restated in their entirety.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
SpringWorks Therapeutics, Inc.: Bylaws amended and restated in their entirety at the effective time of the merger.
- Change
- bylaw amendment
Exact text from the filing
at the Effective Time, SpringWorks’ certificate of incorporation and bylaws were each amended and restated in their entirety.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.95
SpringWorks Therapeutics, Inc. completed an acquisition involving Merck KGaA, Darmstadt, Germany for the right to receive the Per Share Merger Consideration (closed 2025-07-01).
- Action
- acquisition
- Counterparty
- Merck KGaA, Darmstadt, Germany
- Consideration
- the right to receive the Per Share Merger Consideration
- Closing
- 2025-07-01
Exact text from the filing
On July 1, 2025 (the “ Closing Date ”), Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“ Parent ”), completed the previously announced acquisition of SpringWorks Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ SpringWorks ”), pursuant to the Agreement and Plan of Merger, dated April 27, 2025 (the “ Merger Agreement ”), by and among SpringWorks, Parent and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”). Pursuant to the terms of the Merger Agreement, on the Closing Date, Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “ Merger ”).
View on SEC.gov